The software is currently in its 7th version of development and supports following real time PCR chemistries for primer and probe design Beacon Designer is a software that runs on Windows and Macintosh operating systems and designs primers and probes for real time PCR ( polymerase chain reaction). The program has an in-built support for homology avoidance using the standard web BLAST service or the set-up of a desktop BLAST feature for identification of regions that are significantly cross homologous with the target gene sequence. The software is supposed to design critical primers and probes for complex differential gene expression and allele discrimination assays. īeacon Designer has been used in workshops and conferences related to real time PCR study as a reference software Īvoidance of the cross homology renders specificity to the primers in question and they are highly targeted and only amplify the intend sequence and no other targets. The software also supports the design of multiplex PCR reactions with the selection of a reference gene. Premier Biosoft - Infobox Company company name = Premier Biosoft company company type = Private foundation = 1994 location = Palo Alto, California key people = Kay Brown (CEO) homepage = [ footnotes =PREMIER… … Wikipedia The author company, Premier Biosoft has also launched a simple version for evaluation of oligos for real time PCR primers and probes (support limited to TaqMan and SYBR Green primers) by the name Beacon designer free version. Primer (molecular biology) - A primer is a strand of nucleic acid that serves as a starting point for DNA synthesis. They are required for DNA replication because the enzymes that catalyze this process, DNA polymerases, can only add new nucleotides to an existing strand of… … Wikipedia Performing arts - arts or skills that require public performance, as acting, singing, or dancing. * * * ▪ 2009 Introduction Music Classical. Gene Editing: Technology & Applications.The last vestiges of the Cold War seemed to thaw for a moment on Feb. Salivary gland hypofunction causes significant morbidity and loss of quality of life for head and neck cancer patients treated with radiotherapy. Preventing hypofunction is an unmet therapeutic need. Primer and probe design parameters can now be saved as a. The primers are designed such that at least one of the primers from the pair spans one of the junctions selected by the user. We used an adeno-associated virus serotype 2 (AAV2) vector expressing the human neurotrophic factor neurturin (CERE-120) to treat murine submandibular glands either pre- or post-irradiation (IR). Beacon Designer now enables primer design across exon-exon and exon-intron junctions to selectively amplify cDNA from a mixture. Treatment with CERE-120 pre-IR, not post-IR, prevented hypofunction. RNA sequencing (RNA-seq) analysis showed reduced gene expression associated with fibrosis and the innate and humoral immune responses. We then used a minipig model with CERE-120 treatment pre-IR and also compared outcomes of the contralateral non-IR gland. Analysis of gene expression, morphology, and immunostaining showed reduced IR-related immune responses and improved secretory mechanisms. CERE-120 prevented IR-induced hypofunction and restored immune homeostasis, and there was a coordinated contralateral gland response to either damage or treatment. CERE-120 gene therapy is a potential treatment for head and neck cancer patients to influence communication among neuronal, immune, and epithelial cells to prevent IR-induced salivary hypofunction and restore immune homeostasis. Which was measured by pilocarpine stimulation of whole saliva production. Saliva was collected 90 days post-IR, and the IR control group produced ∼65% less saliva compared to the non-IR group (baseline), irrespective of whether the AAV2-GFP was delivered pre- or post-IR ( Figures 1C–1E). All CERE-120 treatments pre-IR (10 6, 10 8, 10 10 vp/g) resulted in improved saliva flow compared to the IR-GFP group and were similar to the non-IR group at 90 and 300 days. At 120 days, there were differences in the 3 doses with CERE-120 at 10 8 and 10 10 vp/g being similar to non-IR. In comparison, CERE-120 post-IR treatment groups only showed similar saliva flow to the non-IR group at 300 days, not at 90 and 120 days post-IR ( Figures 1C and 1D).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |